Skip to content
← Clinical Cases

Chronic Obstructive Pulmonary Disease — clinical cases

29 questions

Sample cases

  1. Case 1

    A 64-year-old man with a 40 pack-year smoking history has chronic cough, sputum and breathlessness on exertion. Spirometry shows: pre-bronchodilator FEV1/FVC 0.66; post-bronchodilator FEV1/FVC 0.64; post-bronchodilator FEV1 71% predicted; FEV1 improved by 6% after salbutamol (albuterol).

    Which finding is the spirometric criterion required for a diagnosis of COPD?

    • A.Post-bronchodilator FEV1/FVC below 0.70
    • B.Post-bronchodilator FEV1 below 80% predicted
    • C.Pre-bronchodilator FEV1/FVC below 0.70
    • D.FEV1 improvement after salbutamol of less than 12%
  2. Case 2

    A 66-year-old woman is newly diagnosed with COPD (post-bronchodilator FEV1 58% predicted). Her COPD Assessment Test (CAT) score is 15 and mMRC dyspnea grade is 2. Five months ago she had one exacerbation treated in her family doctor's office with prednisone and an antibiotic; she has never been to an emergency department or hospital for COPD. Blood eosinophils are 0.15 × 109/L (150 cells/µL). She has no history of asthma and uses salbutamol (albuterol) as needed.

    Which is the most appropriate initial maintenance therapy?

    • A.LAMA monotherapy, e.g. tiotropium
    • B.LAMA/LABA in a single inhaler, e.g. umeclidinium/vilanterol
    • C.ICS/LABA in a single inhaler, e.g. fluticasone/salmeterol
    • D.LAMA/LABA/ICS in a single inhaler, e.g. fluticasone furoate/umeclidinium/vilanterol
  3. Case 3

    According to the 2023 Canadian Thoracic Society (CTS) guideline on pharmacotherapy in stable COPD:

    A 70-year-old man with COPD (post-bronchodilator FEV1 48% predicted, CAT 21, mMRC 3) has had two exacerbations in the past year, each treated as an outpatient with prednisone and an antibiotic. He uses only salbutamol as needed. Blood eosinophils are 0.10 × 109/L (100 cells/µL).

    Which initial maintenance therapy does the guideline recommend?

    • A.LAMA monotherapy, e.g. tiotropium
    • B.LAMA/LABA dual therapy, adding an ICS only if eosinophils reach 0.3 × 109/L
    • C.LAMA/LABA/ICS triple therapy, preferably in a single inhaler
    • D.ICS/LABA combination therapy, e.g. budesonide/formoterol